Savara (SVRA) has released an update.
Savara Inc. has solidified its partnership with Fujifilm’s biotech divisions to advance the development and manufacturing of the active pharmaceutical ingredient for its molgramostim product candidate. This collaboration is outlined in a Master Services Agreement, supplemented by specific work scopes, the first of which involves a significant manufacturing campaign. The agreement, which is detailed for legalities like confidentiality and dispute resolution, allows for termination under certain conditions, ensuring flexibility and protection for both entities as they navigate the intricate process of bringing a pharmaceutical product to market.
For further insights into SVRA stock, check out TipRanks’ Stock Analysis page.
